United Therapeutics Europe

Amodiaquine plus Artesunate co-administration (CKNT_1) is a small-molecule antimalarial combination therapy developed by United Therapeutics Europe Ltd for the treatment of malaria. The program combines two established antiparasitic agents to address parasitic infection through dual mechanisms. Artesunate, the intravenous component, is marketed as GARSUN and has achieved regulatory approval in both the European Union and United States. The combination approach represents a treatment strategy leveraging synergistic antimalarial activity.

The program has completed clinical development and achieved approved status as of the latest milestone dated September 18, 2015. GARSUN (artesunate) received European Union marketing authorization on March 24, 2026, under two product numbers (EMEA/H/C/005550 and EMEA/H/C/005718), with marketing authorization holders including Amivas Ireland Ltd and B And O Pharm. In the United States, artesunate received FDA approval under NDA213036 with AMIVAS as the sponsor.

The program operates within a competitive antimalarial landscape that includes established therapies such as artemether-lumefantrine combinations (Coartem), chloroquine, sulfadoxine-pyrimethamine, and other artesunate-based regimens. The clinical development was supported by trial NCT00550160, which evaluated the co-administration strategy. As an approved therapy, this combination addresses the ongoing global need for effective malaria treatment options, particularly in endemic regions where combination therapy approaches have become standard of care.

Malaria remains a significant global health burden, with hundreds of millions of cases reported annually across endemic regions in Africa, Asia, and Latin America. The development of effective combination antimalarial therapies is critical to combat drug resistance and improve treatment outcomes. The amodiaquine plus artesunate combination addresses the clinical need for reliable, evidence-based treatment regimens that leverage complementary mechanisms of action to maximize parasitological clearance and reduce recrudescence rates.

The combination therapy approach reflects current World Health Organization guidance favoring artemisinin-based combination therapies (ACTs) as first-line treatments for uncomplicated malaria. By combining artesunate with amodiaquine, this program targets both the acute parasitemia phase and residual parasites, potentially improving cure rates compared to monotherapy approaches. The intravenous formulation of artesunate provides rapid drug delivery, which is particularly valuable in severe malaria cases where rapid parasite clearance is essential to prevent complications and mortality.

From a commercial perspective, the approved status of this combination positions it within the established antimalarial market, competing against other ACT formulations and traditional antimalarials. The regulatory approvals in both the EU and US expand potential market access, though uptake will depend on clinical adoption patterns, pricing strategies, and integration into national malaria treatment guidelines. The program's completion and approval status indicate successful translation from clinical development to marketed product, establishing United Therapeutics Europe Ltd as an active participant in antimalarial therapeutics.

Drug Class: Antimalarial combination therapy; antiparasitic products (P01 therapeutic classification)

Modality: Small-molecule combination

Components:

• Artesunate (GARSUN): Intravenous formulation; artemisinin derivative with rapid antimalarial activity; approved in EU (March 24, 2026) and US (NDA213036)
• Amodiaquine: Aminoquinoline antimalarial; oral or parenteral formulation potential

Route of Administration: Intravenous (artesunate component)

Mechanism of Action: Not yet disclosed in available data; presumed to involve artemisinin-based rapid parasite killing (artesunate) combined with amodiaquine's blood schizontocidal activity

Related Therapies: Artemether-lumefantrine (Coartem), artemether-lumefantrine combinations (ALN), artesunate monotherapy, chloroquine, sulfadoxine-pyrimethamine, primaquine

Patent Status: Not yet disclosed

Regulatory Designations: Not yet disclosed

European Union: Artesunate (GARSUN) received marketing authorization on March 24, 2026, under two EMA product numbers (EMEA/H/C/005550 and EMEA/H/C/005718). Marketing authorization holders are Amivas Ireland Ltd and B And O Pharm. Status: Approved.

United States: Artesunate received FDA approval under NDA213036 with AMIVAS as the sponsor. Status: Approved.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Other Jurisdictions: Regulatory status in additional markets not yet disclosed.

Expected Loss of Exclusivity: Not yet disclosed for either component or combination.

Strategic Positioning: The approval of amodiaquine plus artesunate represents successful translation of a combination antimalarial strategy into a marketed product. United Therapeutics Europe Ltd's portfolio approach—maintaining multiple antimalarial classes and combinations—positions the company to serve diverse geographic markets and treatment contexts where drug resistance patterns and clinical guidelines vary.

Regulatory Milestone Significance: The March 2026 EU authorization of GARSUN (artesunate) and prior US FDA approval establish regulatory validation for the intravenous artesunate component. The dual authorization pathway (EU and US) expands potential market access, though commercial success will depend on adoption in endemic regions where treatment decisions are often driven by cost, availability, and national treatment guidelines rather than regulatory status in developed markets.

Competitive Implications: The program faces established competition from artemether-lumefantrine combinations (Coartem) and emerging competition from Phase 3 candidates like tafenoquine. The approved status provides market entry advantage over pipeline competitors, but market share will depend on clinical differentiation, pricing strategy, and integration into WHO-endorsed treatment algorithms.

Future Catalysts: Potential catalysts include expanded regulatory approvals in additional jurisdictions (PMDA, NMPA), label expansions for severe malaria or pediatric indications, and clinical data supporting comparative efficacy or safety advantages. Market penetration in endemic regions will be the primary indicator of commercial success.

Data Gaps: Mechanism of action details, patent status, peak sales projections, and detailed clinical trial results remain not yet disclosed. These gaps limit comprehensive competitive and commercial assessment.